Dulaglutide and Semaglutide are both GLP-1 receptor agonists, primarily studied for their roles in managing Type 2 Diabetes Mellitus. Evidence suggests that Dulaglutide has been associated with a significant reduction in stroke risk in T2DM patients. Semaglutide, on the other hand, has shown a notable reduction in cardiovascular mortality in T2DM patients. Both peptides are part of a class of medications that are increasingly being recognized for benefits extending beyond glycemic control, including cardiovascular protection. The corpus includes a substantial number of studies for both, with Semaglutide having a considerably larger body of research indexed.
| Dulaglutide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 42 | 1011 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | cohort · 1 rct · 15 review · 3 meta analysis · 6 other · 7 | n/a |
| Studies with explicit sample size | 6 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Dulaglutide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Dulaglutide COA records so far — not enough for a meaningful purity aggregate yet. Browse what we have →
We tested 941 Semaglutide batches across 307 manufacturers, 99.54% avg purity.
No direct head-to-head trials in our corpus. Indirect comparison only. While both are GLP-1 receptor agonists, a network meta-analysis found that Dulaglutide reduced stroke risk by 23% (RR: 0.77), whereas Semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients. Semaglutide has also been investigated for its potential link to non-arteritic anterior ischemic optic neuropathy risk, and oral semaglutide 25 mg has shown equivalent exposure to subcutaneous 2.4 mg, leading to greater weight loss in simulated studies. The corpus contains significantly more studies on Semaglutide (729) compared to Dulaglutide (42), suggesting a broader range of research and potentially more extensive data available for Semaglutide, including investigations into areas like Parkinson's disease and combination with exercise for weight loss. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been shown to offer superior glycemic control and weight loss compared to Dulaglutide in meta-analyses.
Looking for vendor-level purity, endotoxin, and HPLC data on Dulaglutide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.